Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315), a leading biotechnology company,  announced a significant collaboration with Gilead Sciences, Inc., a global biopharmaceutical company known for its innovative therapies. The partnership, formalized through an antibody evaluation and option agreement, grants Gilead access to Biocytogen’s expansive fully human antibody library, which has been developed against a broad spectrum of therapeutic targets.

This collaboration marks a strategic alliance in the biopharmaceutical industry, focusing on the discovery and development of novel antibody-based therapeutics. Over the next three years, Gilead will have the opportunity to nominate targets of interest and assess corresponding antibodies from Biocytogen’s library, with an option to acquire rights for the development of selected antibodies for global therapeutic use.

Biocytogen is set to receive an initial payment from Gilead to facilitate the evaluation of antibodies for each nominated target. Additionally, Biocytogen will be eligible for option exercise fees and further financial rewards tied to development, regulatory achievements, and sales milestones for each antibody selected against nominated targets. The agreement also includes provisions for Biocytogen to receive single-digit royalties on net sales of any developed products.

Dr. Yuelei Shen, President and CEO of Biocytogen, expressed enthusiasm about the collaboration, stating, “We are thrilled to collaborate with Gilead, a partner renowned for their drug development and commercialization expertise. Our extensive library of RenMice®-derived, fully human antibodies could serve as an important resource for Gilead to accelerate development of multiple novel antibody-based therapeutics to treat a variety of diseases. We are committed to supporting Gilead as well as our other partners in their drug development endeavors to benefit patients.”

This partnership underscores the commitment of both Biocytogen and Gilead to advancing healthcare and providing new therapeutic options for patients worldwide. The collaboration is poised to leverage Biocytogen’s innovative antibody technology and Gilead’s expertise in drug development and commercialization to bring forward novel treatments for a range of diseases.